Holen Sie sich die Stockscreener-App
50.82
0.47%
0.34
Schlusskurs vom Vortag:
$50.48
Offen:
$50.23
24-Stunden-Volumen:
283.30K
Relative Volume:
0.40
Marktkapitalisierung:
$2.92B
Einnahmen:
$718.95M
Nettoeinkommen (Verlust:
$-38.55M
KGV:
-74.31
EPS:
-0.6839
Netto-Cashflow:
$45.99M
1W Leistung:
+2.77%
1M Leistung:
-5.85%
6M Leistung:
+4.98%
1J Leistung:
+54.91%
1-Tages-Spanne:
$49.82
$51.24
1-Wochen-Bereich:
$49.65
$52.69
52-Wochen-Spanne:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
50.79 | 2.91B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.20 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.66 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
555.64 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo Finance UK
Supernus Pharmaceuticals Inc (S49.DU) stock price, news, quote and history - Yahoo Finance UK
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year - aol.com
Hennion & Walsh Asset Management Inc. Has $4.01 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co. - MarketBeat
Market Trends: Is now the right time to enter Supernus Pharmaceuticals IncWall Street Watch & High Yield Equity Trading Tips - baoquankhu1.vn
Vanguard disaggregates holdings after internal realignment (SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
D&O policy doesn’t cover antitrust suit over drug acquisition: Court - businessinsurance.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Insurer Need Not Cover Parkinson's Drug Antitrust Dispute - Law360
Jefferies reiterates Supernus Pharmaceuticals stock Buy rating By Investing.com - Investing.com South Africa
Jefferies reiterates Supernus Pharmaceuticals stock Buy rating - Investing.com UK
Breakout Watch: What is the target price for Supernus Pharmaceuticals Inc stockQuarterly Growth Report & Low Volatility Stock Suggestions - baoquankhu1.vn
SUPN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Technical Signals Behind (SUPN) That Institutions Follow - news.stocktradersdaily.com
SUPN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
Quarterly Risk: Does Supernus Pharmaceuticals Inc have strong EBITDA margins2026 Technicals & High Accuracy Buy Signal Tips - baoquankhu1.vn
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock - MarketBeat
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus Pharmaceuticals Q4 2025 earnings preview - MSN
SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise - Stock Titan
SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Supernus Pharmaceuticals CEO Sells $1.76M in Stock - National Today
Insider Sell Alert: Frederick Hudson Sells Shares of Supernus Ph - GuruFocus
[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Supernus (NASDAQ: SUPN) CEO-linked KBT Trust sells 35,000 shares under 10b5-1 plan - Stock Titan
Director at Supernus (NASDAQ: SUPN) sells 5,369 shares - Stock Titan
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns - simplywall.st
Aristotle Capital Boston LLC Sells 503,122 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Insider sale of 5,369 shares at SUPN (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals Stock Review: Valuation & Business Quality ConcernsNews and Statistics - IndexBox
3 Reasons SUPN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Supernus at Barclays Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc. - MarketBeat
Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus (NASDAQ: SUPN) CEO exercises performance units, withholds shares for taxes - Stock Titan
Supernus (SUPN) SVP Mottola sells shares after exercising 3,750 PSUs - Stock Titan
SUPERNUS (NASDAQ: SUPN) CFO exercises performance units, settles taxes in shares - Stock Titan
Supernus (NASDAQ: SUPN) SVP sells 8,877 shares after exercising 7,500 PSUs - Stock Titan
[Form 3] SUPERNUS PHARMACEUTICALS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc. - MarketBeat
Victory Capital Management Reduces Stake in Supernus Pharmaceuticals - National Today
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):